Synartro is a Swedish life science company developing local injection treatments to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our novel delivery technology with existing proven drugs. Our lead program focuses on a novel therapy using our compound SYN321 for the treatment of symptomatic osteoarthritis (OA). This disease leaves up to 50% of patients without adequate pain relief.In addition to the founders, major shareholders include life science investment company Linc AB.